|
Table of Contents:
Chapter Availability
Individual chapters are available for $25 each by sending an email to novascience@earthlink.net. Nova will provide the chapter for your easy downloading or send it as an email attachment if you prefer.
Preface
Chapter I - Risk Stratification in the Management of Chronic Lymphocytic Leukemia (CLL); pp. 1-15)
(Chadi Nabhan (Lutheran General Cancer Center)
Chapter II - New Research in Chronic Lymphocytic Leukemia; pp. 17-34
(Zhang J. Zhong and Maher Albitar (Quest Diagnostics Nichols Inst., San Juan Capistrano, CA)
Chapter III - Transplantation Strategies for the Treatment of Chronic Lymphocytic Leukemia; pp. 35-75
(Edgardo S. Santos (Div. of Hematology-Oncology, Tulane Univ. Sch. of Medicine, New Orleans, LA), and Mohamed A. Kharfan-Dabaja (Div. of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Inst., Tampa, FL)
Chapter IV - What is the Clinical and Biological Significance of the BCL-2 Family n Apoptosis Regulation in B-Cell Chronic Lymphocytic Leukemia (CLL)?; pp. 77-111
By Anurag Saxena and Oksana Moshynska (Dept. of Pathology and Lab. Medicine, Saskatoon Health Region and Univ. of Saskatchewan, Saskatoon, Saskatchewan, Canada)
Chapter V - Mode of Action of Rituximab in Chronic Lymphocytic Leukemia; Activation of Tis11b, an Inducer of MRNA Instability and Induction of Apoptosis; pp. 113-127
(Maria Baou (Sch. of Life Sciences, Kingston Univ., Surrey, UK), (Immunology Dept., King's College London, UK), Andrew P. Jewell (Fac. of Health and Social Care Sciences, Kingston Univ. and St. George's Univ. of London, UK), Kwee L. Yong (Haematology Dept., Univ. College London), and John Murphy (Immunology Dept., King's College London, UK)
Chapter VI - Genetic Factors Impacting the Biology of B Cell Chronic Lymphocytic Leukemia (B-CLL); pp. 129-141
(Vasantha Brito-Babapulle (Haemato-Oncolology, Inst. of Cancer Research, Royal Marsaden Hosp., Surrey, UK)
Chapter VII - The "In Vitro Apoptosis" Profile in CLL Correlates with some Prognostic Markers, Treatment History and In Vivo Response to Treatment; pp. 143-163
(A. Janssens, F. Offner, H. Thierens, and J. Philippe (Dept. of Haematology, Univ. Hosp. Ghent, Dept. of Radiopharmacy and Biomedical Physics, Ghent Univ., Dept. of Clinical Chemistry, Microbiology and Immunology, Univ. Hosp. Ghent, Belgium)
Chapter VIII - CD38 Expression in B-Cell Chronic Lymphocytic Leukemia: What have we learned?; pp. 165-181
(Giovanni D'Arena (Hematology Oncology Unit, Nat. Cancer Inst., Naples Italy), Tiziana Vaisitti, Semra Aydin, and Silvia Deaglio (Lymphocyte Signaling Unit, Lab. of Immunogenetics, Dept. of Genetics, Biology and Biochemistry and CERMS, Univ. of Torino, Medical Sch., Torino, Italy)
Chapter IX - Novel and Uncommon Chromosome Abberations in Chronic-Lymphocytic Leukemia: Cytogenetic, FISH and Clinical Evaluation;
pp. 183-213
(Roxana Cerretini (Dept. de Genetica Experimental, Centro Nacional de Genetica Medica, Buenos Aires, Argentina), (Dept. de Genetica, Inst. de Investigaciones Hematologicas, Academia Nat. de Medicina, Buenos Aires, Argentina), Christian Chena, and Irma Slavutsky (Dept. de Genetica, Inst. de Investigaciones Hematologicas, Academia Nat. de Medicina, Buenos Aires, Argentina)
Index |
